If you typed Avance Clinical into a search box, you are probably building a CRO shortlist. This article uses only what Avance Clinical publishes (www.avancecro.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What Avance Clinical publishes
Avance Clinical is an Adelaide-headquartered biotech CRO, formerly the clinical arm of CPR Pharma, with operations in Australia, New Zealand, Asia, North America and Europe. In January 2025 Avance said it was CRO of record on more than 52% of active Phase I trials on ANZCTR and that more than 80% of its clients are US biotechs. It runs an Early Phase Center of Excellence that places studies into Australian Phase I units.
Avance Clinical vs bioaccess®
| Dimension | Avance Clinical | bioaccess® |
|---|---|---|
| Core focus | Biotech full-service CRO, early phase | First-in-human and early feasibility studies for medical devices |
| Geography | Australia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you are a US biotech running an Australian Phase I drug trial, Avance is one of the most established choices.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Avance Clinical, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Avance Clinical features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the Avance Clinical public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply